Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms- |
Target- |
Action enhancers |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenomatous Polyposis Coli | Phase 1 | China | 01 May 2024 | |
Neoplasm Metastasis | Phase 1 | China | 01 May 2024 |
Not Applicable | - | (18F-FDG PET/CT) | zeimwrvpvv(huypqcvuzm) = zyxrjtcurd eilggsowtt (hzevfpxzka ) | - | 28 Aug 2023 | ||
Not Applicable | - | (18F-FDG PET/CT) | jsveyqrwbv(mzllfcxfrk) = 68Ga-FAPI-RGD was well tolerated, with no adverse events reported in correlation with the study in any of the patient bkjirsvwap (leicblykwd ) | - | 28 Aug 2023 |